This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum

Early Bird Price ends in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Marina Bay Sands Convention Center
April 24—25, 2024 | SingaporeApril 29—30, 2024 | Virtual

Glycostem Therapeitics B.V.

Profile

Glycostem® Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). Our mission is to focus on the research, development, production and medical use of NK cells based therapies and work with selected partners looking after patients, staff and the environment. Our vision is to be the leading innovative NK cell therapy company covering strong unmet medical needs. Future Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK cell production processes. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production. During our phase I safety study we verified our lead product oNKord® (unmodified NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second product: Chimeric Antigen Receptor (CAR)-engineered NK cells. This second-generation product has dedicated functionality, enhances tumor targeting and prolongs persistence.